| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, University Hospital, Lausanne, Switzerland;
Unit 463, Institut National de la Santé et de la Recherche Médicale, Nantes, France;
Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland;
§
Instituto de Inmunologia, Universidad del Valle, Cali, Colombia;
¶
Centre Pluridisciplinaire d’Oncologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; and
||
Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
HLA-A*0201 melanoma patients often develop a CTL response to an immunodominant peptide derived from the melanocyte lineage-specific protein Melan-A/MART-1. We have shown previously that the antigenic peptide most often involved is the decapeptide Melan-A26–35 (EAAGIGILTV). We also observed some clonal diversity in the fine specificity of Melan-A-specific CTL. To substantiate this observation, we have now tested a series of Melan-A26–35 variant peptides containing single alanine substitutions for binding to HLA-A*0201 and recognition by polyclonal and monoclonal Melan-A-specific CTL. Substitution of several residues with alanine reduced peptide binding activity by >10-fold. In contrast, substitution of E26 with alanine (AAAGIGILTV) resulted in a 5-fold higher binding activity as well as in stronger stability of the corresponding HLA-A*0201/peptide complexes. Interestingly, the peptide variant AAAGIGILTV was recognized more efficiently than the natural decapeptide by short term cultured, tumor-infiltrated lymph node cell cultures and a number of Melan-A-specific CTL clones derived from different individuals. Moreover, this analysis revealed that the fine specificity of the CTL response to the Melan-A immunodominant epitope is quite diverse at the clonal level. At least three distinct patterns of fine specificity were identified. This diversity appears to reflect the diversity of the TCR repertoire available for this Ag, since similar results were obtained with a panel of Melan-A-specific CTL clones derived from a single melanoma patient. These findings have important implications for the formulation of Melan-A peptide-based vaccines as well as for the monitoring of Melan-A-specific CTL responses in melanoma patients.
This article has been cited by other articles:
|
|
 |
|
  L. Derre, M. Ferber, C. Touvrey, E. Devevre, V. Zoete, A. Leimgruber, P. Romero, O. Michielin, F. Levy, and D. E. Speiser A Novel Population of Human Melanoma-Specific CD8 T Cells Recognizes Melan-AMART-1 Immunodominant Nonapeptide but Not the Corresponding Decapeptide J. Immunol., December 1, 2007; 179(11): 7635 - 7645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Cortez-Gonzalez, J. Sidney, O. Adotevi, A. Sette, F. Millard, F. Lemonnier, P. Langlade-Demoyen, and M. Zanetti Immunogenic HLA-B7-restricted peptides of hTRT Int. Immunol., December 1, 2006; 18(12): 1707 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Ouyang, N. E. Standifer, H. Qin, P. Gottlieb, C. B. Verchere, G. T. Nepom, R. Tan, and C. Panagiotopoulos Recognition of HLA Class I-Restricted {beta}-Cell Epitopes in Type 1 Diabetes Diabetes, November 1, 2006; 55(11): 3068 - 3074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Colombetti, T. Fagerberg, P. Baumgartner, L. Chapatte, D. E. Speiser, N. Rufer, O. Michielin, and F. Levy Impact of Orthologous Melan-A Peptide Immunizations on the Anti-Self Melan-A/HLA-A2 T Cell Cross-Reactivity. J. Immunol., June 1, 2006; 176(11): 6560 - 6567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yang, K.-Y. Tsang, and J. Schlom Induction of Higher-Avidity Human CTLs by Vector-Mediated Enhanced Costimulation of Antigen-Presenting Cells Clin. Cancer Res., August 1, 2005; 11(15): 5603 - 5615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. V. Yamshchikov, D. W. Mullins, C.-C. Chang, T. Ogino, L. Thompson, J. Presley, H. Galavotti, W. Aquila, D. Deacon, W. Ross, et al. Sequential Immune Escape and Shifting of T Cell Responses in a Long-Term Survivor of Melanoma J. Immunol., June 1, 2005; 174(11): 6863 - 6871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Rubio-Godoy, V. Dutoit, Y. Zhao, R. Simon, P. Guillaume, R. Houghten, P. Romero, J.-C. Cerottini, C. Pinilla, and D. Valmori Positional Scanning-Synthetic Peptide Library-Based Analysis of Self- and Pathogen-Derived Peptide Cross-Reactivity with Tumor-Reactive Melan-A-Specific CTL J. Immunol., November 15, 2002; 169(10): 5696 - 5707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hernandez, F. Garcia-Pons, Y. C. Lone, H. Firat, J. D. Schmidt, P. Langlade-Demoyen, and M. Zanetti Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells PNAS, September 17, 2002; 99(19): 12275 - 12280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Valmori, V. Dutoit, V. Schnuriger, A.-L. Quiquerez, M. J. Pittet, P. Guillaume, V. Rubio-Godoy, P. R. Walker, D. Rimoldi, D. Lienard, et al. Vaccination with a Melan-A Peptide Selects an Oligoclonal T Cell Population with Increased Functional Avidity and Tumor Reactivity J. Immunol., April 15, 2002; 168(8): 4231 - 4240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Rubio-Godoy, C. Pinilla, V. Dutoit, E. Borras, R. Simon, Y. Zhao, J.-C. Cerottini, P. Romero, R. Houghten, and D. Valmori Toward Synthetic Combinatorial Peptide Libraries in Positional Scanning Format (PS-SCL)-based Identification of CD8+ Tumor-reactive T-Cell Ligands: A Comparative Analysis of PS-SCL Recognition by a Single Tumor-reactive CD8+ Cytolytic T-Lymphocyte Clone Cancer Res., April 1, 2002; 62(7): 2058 - 2063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Puente Navazo, D. Valmori, and C. Ruegg The Alternatively Spliced Domain TnFnIII A1A2 of the Extracellular Matrix Protein Tenascin-C Suppresses Activation-Induced T Lymphocyte Proliferation and Cytokine Production J. Immunol., December 1, 2001; 167(11): 6431 - 6440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Rimoldi, K. Muehlethaler, S. Salvi, D. Valmori, P. Romero, J.-C. Cerottini, and F. Levy Subcellular Localization of the Melanoma-associated Protein Melan-AMART-1 Influences the Processing of Its HLA-A2-restricted Epitope J. Biol. Chem., November 9, 2001; 276(46): 43189 - 43196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Morel, A. Truneh, R. W. Sweet, D. Olive, and R. T. Costello The TNF Superfamily Members LIGHT and CD154 (CD40 Ligand) Costimulate Induction of Dendritic Cell Maturation and Elicit Specific CTL Activity J. Immunol., September 1, 2001; 167(5): 2479 - 2486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pinilla, V. Rubio-Godoy, V. Dutoit, P. Guillaume, R. Simon, Y. Zhao, R. A. Houghten, J.-C. Cerottini, P. Romero, and D. Valmori Combinatorial Peptide Libraries as an Alternative Approach to the Identification of Ligands for Tumor-reactive Cytolytic T Lymphocytes Cancer Res., July 1, 2001; 61(13): 5153 - 5160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-Y. Dietrich, P. R. Walker, A.-L. Quiquerez, G. Perrin, V. Dutoit, D. Liénard, P. Guillaume, J.-C. Cerottini, P. Romero, and D. Valmori Melanoma Patients Respond to a Cytotoxic T Lymphocyte-defined Self-Peptide with Diverse and Nonoverlapping T-Cell Receptor Repertoires Cancer Res., March 1, 2001; 61(5): 2047 - 2054. [Abstract] [Full Text]
|
|
|
|
|
|
D. Rimoldi, V. Rubio-Godoy, V. Dutoit, D. Lienard, S. Salvi, P. Guillaume, D. Speiser, E. Stockert, G. Spagnoli, C. Servis, et al. Efficient Simultaneous Presentation of NY-ESO-1/LAGE-1 Primary and Nonprimary Open Reading Frame-Derived CTL Epitopes in Melanoma J. Immunol., December 15, 2000; 165(12): 7253 - 7261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Migliaccio, M. Amacker, T. Just, P. Reichenbach, D. Valmori, J.-C. Cerottini, P. Romero, and M. Nabholz Ectopic Human Telomerase Catalytic Subunit Expression Maintains Telomere Length But Is Not Sufficient for CD8+ T Lymphocyte Immortalization J. Immunol., November 1, 2000; 165(9): 4978 - 4984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Valmori, V. Dutoit, D. Liénard, D. Rimoldi, M. J. Pittet, P. Champagne, K. Ellefsen, U. Sahin, D. Speiser, F. Lejeune, et al. Naturally Occurring Human Lymphocyte Antigen-A2 Restricted CD8+ T-Cell Response to the Cancer Testis Antigen NY-ESO-1 in Melanoma Patients Cancer Res., August 1, 2000; 60(16): 4499 - 4506. [Abstract] [Full Text]
|
|
|
|
|
|
D. Valmori, V. Dutoit, D. Lienard, F. Lejeune, D. Speiser, D. Rimoldi, V. Cerundolo, P.-Y. Dietrich, J.-C. Cerottini, and P. Romero Tetramer-Guided Analysis of TCR {beta}-Chain Usage Reveals a Large Repertoire of Melan-A-Specific CD8+ T Cells in Melanoma Patients J. Immunol., July 1, 2000; 165(1): 533 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Valmori, F. Levy, I. Miconnet, P. Zajac, G. C. Spagnoli, D. Rimoldi, D. Lienard, V. Cerundolo, J.-C. Cerottini, and P. Romero Induction of Potent Antitumor CTL Responses by Recombinant Vaccinia Encoding a Melan-A Peptide Analogue J. Immunol., January 15, 2000; 164(2): 1125 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Valmori, J.-F. Fonteneau, S. Valitutti, N. Gervois, R. Dunbar, D. Lienard, D. Rimoldi, V. Cerundolo, F. Jotereau, J.-C. Cerottini, et al. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues Int. Immunol., December 1, 1999; 11(12): 1971 - 1980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Valmori, M. J. Pittet, C. Vonarbourg, D. Rimoldi, D. Lienard, D. Speiser, R. Dunbar, V. Cerundolo, J.-C. Cerottini, and P. Romero Analysis of the Cytolytic T Lymphocyte Response of Melanoma Patients to the Naturally HLA-A*0201-associated Tyrosinase Peptide 368-376 Cancer Res., August 1, 1999; 59(16): 4050 - 4055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Valmori, M. J. Pittet, D. Rimoldi, D. Lienard, R. Dunbar, V. Cerundolo, F. Lejeune, J.-C. Cerottini, and P. Romero An Antigen-targeted Approach to Adoptive Transfer Therapy of Cancer Cancer Res., May 1, 1999; 59(9): 2167 - 2173. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
